@fda.gov grants Priority Review to iberdomide for #RRMM.
• Target: E3 ligase modulator (CELMoD)
• Phase 3 EXCALIBUR results: Improved PFS
• Target action date: May 2026
Insights via @medicalprofref.bsky.social.
Read the review: https://bit.ly/3Olgg0s
#mmsm #MultipleMyeloma #FDA